Curettage and allograft reconstruction for giant cell tumours.

T. Morii, H. Yabe, H. Morioka, Y. Suzuki, U. Anazawa, Y. Toyama

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

PURPOSE: To evaluate treatment outcomes in patients with giant cell tumours after curettage and allograft reconstruction and to identify the risk factors for poor oncological and functional outcome. METHODS: 29 patients with giant cell tumours of bone who underwent curettage and allograft reconstruction were retrospectively reviewed. The adjuvants used were heat treatment by electrocautery and hot water. Types of allograft used, time to bone union, complications, functional outcomes, and risk factors for poor function were analysed. RESULTS: The mean time to bone union was 2.8 (range, 1-5) months. In 7 patients the tumours recurred (6 within 2 years); the 5-year recurrence-free survival rate was 77%. Three recurrences were classified as grade III and 4 as grade II; recurrence and the Campanacci grade showed a trend towards association (p=0.06). Tumour in the distal femur was a risk factor for postoperative fracture (p=0.02). Functional outcomes were excellent in 20 patients, good in 6, fair in 2, and a failure in one. The risk factors for poor function were recurrence (p=0.002) and joint instability (p=0.008) but not the Campanacci grade (p=0.10) or postoperative fracture (p=0.76). Lung metastasis, infection, and non-union were not encountered. CONCLUSION: Despite a relatively high recurrence rate (24%), 26 (90%) of the 29 patients had excellent/good functional outcomes. We recommend the use of adjuvants and allografts for the management of giant cell tumours.

Original languageEnglish
Pages (from-to)75-79
Number of pages5
JournalJournal of orthopaedic surgery (Hong Kong)
Volume16
Issue number1
Publication statusPublished - 2008 Apr

Fingerprint

Giant Cell Tumors
Curettage
Allografts
Recurrence
Giant Cell Tumor of Bone
Joint Instability
Bone and Bones
Electrocoagulation
Femur
Neoplasms
Survival Rate
Hot Temperature
Neoplasm Metastasis
Lung
Water
Infection

ASJC Scopus subject areas

  • Surgery

Cite this

Morii, T., Yabe, H., Morioka, H., Suzuki, Y., Anazawa, U., & Toyama, Y. (2008). Curettage and allograft reconstruction for giant cell tumours. Journal of orthopaedic surgery (Hong Kong), 16(1), 75-79.

Curettage and allograft reconstruction for giant cell tumours. / Morii, T.; Yabe, H.; Morioka, H.; Suzuki, Y.; Anazawa, U.; Toyama, Y.

In: Journal of orthopaedic surgery (Hong Kong), Vol. 16, No. 1, 04.2008, p. 75-79.

Research output: Contribution to journalArticle

Morii, T, Yabe, H, Morioka, H, Suzuki, Y, Anazawa, U & Toyama, Y 2008, 'Curettage and allograft reconstruction for giant cell tumours.', Journal of orthopaedic surgery (Hong Kong), vol. 16, no. 1, pp. 75-79.
Morii T, Yabe H, Morioka H, Suzuki Y, Anazawa U, Toyama Y. Curettage and allograft reconstruction for giant cell tumours. Journal of orthopaedic surgery (Hong Kong). 2008 Apr;16(1):75-79.
Morii, T. ; Yabe, H. ; Morioka, H. ; Suzuki, Y. ; Anazawa, U. ; Toyama, Y. / Curettage and allograft reconstruction for giant cell tumours. In: Journal of orthopaedic surgery (Hong Kong). 2008 ; Vol. 16, No. 1. pp. 75-79.
@article{3dbde19110b4478cbf89c1e64ec20ee5,
title = "Curettage and allograft reconstruction for giant cell tumours.",
abstract = "PURPOSE: To evaluate treatment outcomes in patients with giant cell tumours after curettage and allograft reconstruction and to identify the risk factors for poor oncological and functional outcome. METHODS: 29 patients with giant cell tumours of bone who underwent curettage and allograft reconstruction were retrospectively reviewed. The adjuvants used were heat treatment by electrocautery and hot water. Types of allograft used, time to bone union, complications, functional outcomes, and risk factors for poor function were analysed. RESULTS: The mean time to bone union was 2.8 (range, 1-5) months. In 7 patients the tumours recurred (6 within 2 years); the 5-year recurrence-free survival rate was 77{\%}. Three recurrences were classified as grade III and 4 as grade II; recurrence and the Campanacci grade showed a trend towards association (p=0.06). Tumour in the distal femur was a risk factor for postoperative fracture (p=0.02). Functional outcomes were excellent in 20 patients, good in 6, fair in 2, and a failure in one. The risk factors for poor function were recurrence (p=0.002) and joint instability (p=0.008) but not the Campanacci grade (p=0.10) or postoperative fracture (p=0.76). Lung metastasis, infection, and non-union were not encountered. CONCLUSION: Despite a relatively high recurrence rate (24{\%}), 26 (90{\%}) of the 29 patients had excellent/good functional outcomes. We recommend the use of adjuvants and allografts for the management of giant cell tumours.",
author = "T. Morii and H. Yabe and H. Morioka and Y. Suzuki and U. Anazawa and Y. Toyama",
year = "2008",
month = "4",
language = "English",
volume = "16",
pages = "75--79",
journal = "Journal of orthopaedic surgery (Hong Kong)",
issn = "1022-5536",
publisher = "Hong Kong Academy of Medicine Press",
number = "1",

}

TY - JOUR

T1 - Curettage and allograft reconstruction for giant cell tumours.

AU - Morii, T.

AU - Yabe, H.

AU - Morioka, H.

AU - Suzuki, Y.

AU - Anazawa, U.

AU - Toyama, Y.

PY - 2008/4

Y1 - 2008/4

N2 - PURPOSE: To evaluate treatment outcomes in patients with giant cell tumours after curettage and allograft reconstruction and to identify the risk factors for poor oncological and functional outcome. METHODS: 29 patients with giant cell tumours of bone who underwent curettage and allograft reconstruction were retrospectively reviewed. The adjuvants used were heat treatment by electrocautery and hot water. Types of allograft used, time to bone union, complications, functional outcomes, and risk factors for poor function were analysed. RESULTS: The mean time to bone union was 2.8 (range, 1-5) months. In 7 patients the tumours recurred (6 within 2 years); the 5-year recurrence-free survival rate was 77%. Three recurrences were classified as grade III and 4 as grade II; recurrence and the Campanacci grade showed a trend towards association (p=0.06). Tumour in the distal femur was a risk factor for postoperative fracture (p=0.02). Functional outcomes were excellent in 20 patients, good in 6, fair in 2, and a failure in one. The risk factors for poor function were recurrence (p=0.002) and joint instability (p=0.008) but not the Campanacci grade (p=0.10) or postoperative fracture (p=0.76). Lung metastasis, infection, and non-union were not encountered. CONCLUSION: Despite a relatively high recurrence rate (24%), 26 (90%) of the 29 patients had excellent/good functional outcomes. We recommend the use of adjuvants and allografts for the management of giant cell tumours.

AB - PURPOSE: To evaluate treatment outcomes in patients with giant cell tumours after curettage and allograft reconstruction and to identify the risk factors for poor oncological and functional outcome. METHODS: 29 patients with giant cell tumours of bone who underwent curettage and allograft reconstruction were retrospectively reviewed. The adjuvants used were heat treatment by electrocautery and hot water. Types of allograft used, time to bone union, complications, functional outcomes, and risk factors for poor function were analysed. RESULTS: The mean time to bone union was 2.8 (range, 1-5) months. In 7 patients the tumours recurred (6 within 2 years); the 5-year recurrence-free survival rate was 77%. Three recurrences were classified as grade III and 4 as grade II; recurrence and the Campanacci grade showed a trend towards association (p=0.06). Tumour in the distal femur was a risk factor for postoperative fracture (p=0.02). Functional outcomes were excellent in 20 patients, good in 6, fair in 2, and a failure in one. The risk factors for poor function were recurrence (p=0.002) and joint instability (p=0.008) but not the Campanacci grade (p=0.10) or postoperative fracture (p=0.76). Lung metastasis, infection, and non-union were not encountered. CONCLUSION: Despite a relatively high recurrence rate (24%), 26 (90%) of the 29 patients had excellent/good functional outcomes. We recommend the use of adjuvants and allografts for the management of giant cell tumours.

UR - http://www.scopus.com/inward/record.url?scp=58149183964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149183964&partnerID=8YFLogxK

M3 - Article

C2 - 18453664

AN - SCOPUS:58149183964

VL - 16

SP - 75

EP - 79

JO - Journal of orthopaedic surgery (Hong Kong)

JF - Journal of orthopaedic surgery (Hong Kong)

SN - 1022-5536

IS - 1

ER -